Charles River Laboratories International (CRL) vs IQVIA (IQV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Charles River Laboratories International (CRL) has outperformed IQVIA (IQV) over the past year, gaining 71.8% versus a gain of 29.1%. Over five years, IQV leads with a +4.0% price change compared with -26.2% for CRL. IQVIA is the larger company by market cap ($43.16 billion vs $14.55 billion), about 3.0 times the size.
On valuation, IQVIA trades at a lower forward P/E (18.2x vs 23.6x for Charles River Laboratories International). IQVIA converts more of its revenue into profit, with a net margin of 8.3% versus -3.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRL | IQV |
|---|---|---|
| Share price | $302.02 | $262.23 |
| Market cap | $14.55B | $43.16B |
| 1-day change | +1.35% | +1.29% |
| YTD return | +49.39% | +14.85% |
| 1-year return | +71.79% | +29.05% |
| 5-year return | -26.15% | +4.03% |
| P/E ratio (TTM) | — | 32.58 |
| Forward P/E | 23.64 | 18.17 |
| EPS (TTM) | $-4.80 | $8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.02B | $16.31B |
| Revenue growth (YoY) | -0.85% | +5.87% |
| Net income (latest FY) | $-144.34M | $1.36B |
| Gross margin | — | 33.29% |
| Operating margin | 0.63% | 13.38% |
| Net margin | -3.59% | 8.34% |
| 52-week high | $333.30 | $277.40 |
| 52-week low | $146.20 | $154.50 |
| Distance from 52-week high | -9.38% | -5.47% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +0.99% | +10.91% |
| Average volume | 956.13K | 1.45M |
| Shares outstanding | 48.17M | 164.60M |
| Employees | 18,300 | 94,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IQVIA is about 3.0 times larger than Charles River Laboratories International by market value ($43.16B vs $14.55B).
- CRL has outperformed IQV by 42.7 percentage points over the past year.
- IQVIA is more profitable, keeping 8.3 cents of every revenue dollar as net income versus -3.6 cents for Charles River Laboratories International.
- IQVIA grew revenue faster in its latest fiscal year (+5.87% vs -0.85%).
About Charles River Laboratories International
CRL stock →Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 18,300 employees
About IQVIA
IQV stock →IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 94,000 employees
CRL vs IQV FAQ
Which is bigger, Charles River Laboratories International or IQVIA?
IQVIA (IQV) is larger, with a market capitalization of $43.16B compared with $14.55B for Charles River Laboratories International (CRL).
Which stock has performed better over the past year, CRL or IQV?
CRL returned +71.79% over the past 12 months, compared with +29.05% for IQV (price return, excluding dividends). Past performance does not predict future results.
Are Charles River Laboratories International and IQVIA in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.